AstraZeneca plc (ADR)

  • 3 PDUFA Dates That Will Kickoff 2014

    By Brandy Betz - August 19, 2013 | Tickers: AZN, BMRN, BMY

    The phrase “PDUFA date” is thrown around frequently when discussing biotech and pharma companies. PDUFA stands for the Prescription Drug User Fee Act, which is a law allowing the Food and Drug Administration to charge companies that file new drug applications. The money goes towards expediting the review process that takes six months for drugs with an accelerated approval and ten months for a standard filing. Adding the appropriate number more »

  • Acquisitions Can’t Save Falling Revenues and Dividend Yield

    By Mohsin Saeed - August 19, 2013 | Tickers: AMRN, AZN, OMTH

    AstraZeneca (NYSE: AZN) has been badly hit by the patent cliff. Its key franchises, Crestor and Seroquel, are facing generic threat after losing patent protection in multiple countries. There has been a sharp decline in sales, and management seems unable to stem the flow.

    The company has made some smart acquisitions, but none of the assets will pay off before the end of 2016. It has recently acquired Omthera (NASDAQ: OMTHmore »)

  • 4 Reasons I'm Not Bullish on This Biotech

    By Kanak Kanti - August 14, 2013 | Tickers: AZN, BAYRY.PK, NBIX

    Neurocrine Biosciences (NASDAQ: NBIX) has gained significantly in the last few months based on positive trial results, news of collaborations, and the general unfathomable nature of the stock market. However, this stock looks like a value trap right now, for four reasons.

    Few products in the near-term pipeline

    Neurocrine has 11 programs in various stages of research and development, of which six programs are in clinical stages. However, except for more »

  • This Company's Debt Might Be a Concern

    By Harriet Tramer - August 9, 2013 | Tickers: AZN, GSK, NVS

    GlaxoSmithKline (NYSE: GSK) has been accused of making illegal payments to Chinese doctors and government officials by siphoning them through travel agencies. If these allegations are substantiated -- Glaxo officials at the highest levels have acknowledged that company executives might have broken the law -- they could have serious ramifications for the firm’s future. By some accounts, however, these entanglements are simply the price of doing business, something that companies move more »

  • GlaxoSmithKline: Victim or Villain in China?

    By Victor Alagbe - August 7, 2013 | Tickers: AZN, GSK, JNJ, SNY

    The last reported record of something British forcing drugs on the Chinese people was during the opium wars of which we should let sleeping dogs lie. However, it appears that GlaxoSmithKline (NYSE: GSK), a British company has been caught in the act forcing drugs on the Chinese people albeit through prescriptions. The story of GSK's bribery scandal in China is no longer news; but I would like to point more »

  • A Safe Investment With Growth Promise

    By Mohsin Saeed - August 6, 2013 | Tickers: AZN, PFE, TEVA

    Teva Pharmaceuticals (NYSE: TEVA) has been stuck is share purgatory for a number of years. There have been no capital gains, and the dividend yield is mediocre at best. This has forced Teva to undertake a radical overhaul of its business strategy.

    The recently-released second quarter results did not reflect the effects of this improved business strategy. Teva barely managed to meet expectations, with margins and revenues below expectations.

    However more »

  • Can Acquisitions Save The Declining Revenues?

    By Mohsin Saeed - August 6, 2013 | Tickers: AMRN, AZN, OMTH

    AstraZeneca (NYSE: AZN) is one of the worst affected companies by the patent cliff. It key franchises, Crestor and Seroquel, are facing generic threat after losing patent protection in multiple countries. Despite the best efforts of its new management, the revenues continue to decline.

    The company has made some good acquisitions, but none of the assets will pay off before the end of 2016. It has recently acquired Omthera (NASDAQ: OMTHmore »)

  • This Cancer Biotech Is Looking for Other Green Pastures

    By Kanak Kanti - August 1, 2013 | Tickers: ARRY, AZN, GSK

    Array Biopharma  (NASDAQ: ARRY), a biotech company primarily focused on discovery of drugs for cancer treatment, is making forays into the asthma market. The company recently announced encouraging results – 6.8% improvement in FEV1 versus placebo – of Phase II clinical trials of ARRY-502, an oral medication for management and treatment of asthma. FEV1 (forced expiratory volume in one second) is a measure of lung function and one of the parameters more »

  • 3 Companies With Dividend Yields You Don’t Want to Miss

    By Madhukar Dubey - July 31, 2013 | Tickers: AZN, SNP, JHX

    Several companies are striving hard to manage their business and retain investors by providing an attractive dividend. These days, investors prefer a dividend stock over low interest rates. I'll discuss three companies sporting a dividend yield of more than 6% and see how they are looking to generate sufficient profits in order to provide investors with a fat dividend.

    Asset acquisition to improve returns

    In order to expand upstream more »

  • Will This Biotech Bidding War Lead You to Larger Gains?

    By Sherrie Stone - July 24, 2013 | Tickers: AMGN, AZN, NVS, ONXX, PFE

    Onyx Pharmaceuticals (NASDAQ: ONXX) added 3% to its one-month 60% gains on Monday because of continued speculation of a buyout. Reportedly, four companies are prepping bids to acquire Onyx. What is a fair price for the company, and should you buy now?

    Why the Interest?

    If $120 a share significantly undervalues the company, according to Onyx, then what is a fair price? This question can only be answered when you more »

  • Big Pharma’s Bribery Blues

    By Leo Sun - July 24, 2013 | Tickers: AZN, LLY, GSK, PFE

    Big pharmaceutical companies have a knack for getting into trouble with governments. Over the past four years, major names in big pharma - including Pfizer (NYSE: PFE), Novartis and GlaxoSmithKline (NYSE: GSK) - have been fined billions of dollars in the United States for giving physicians kickbacks and perks to promote off-label marketing.

    This month, charges of bribery have surfaced in China. The Chinese government is currently investigating GlaxoSmithKline for allegedly running more »

  • 3 Healthcare Stocks for Growth and Dividends

    By Ishtiaq Ahmed - July 23, 2013 | Tickers: AZN, GSK, PFE

    The healthcare sector has been one of the best sectors for dividend hunters -- most of the companies operating in the sector generate massive cash flow and payout a large chunk in dividends. Despite tight regulations and hefty investment in new technologies, these companies have been able to generate impressive growth figures.

    GlaxoSmithKline (NYSE: GSK), Pfizer (NYSE: PFE), and AstraZeneca (NYSE: AZN) are some of the star performers of the industry more »

  • The Diabetes Pipeline With a Clog

    By Brandy Betz - July 22, 2013 | Tickers: AZN, BMY, LLY, JNJ

    Big pharma placed its bets on a new class of diabetes drugs called SGLT2. Last year, buzz surrounded late-stage projects from Johnson and Johnson (NYSE: JNJ), Eli Lilly (NYSE: LLY), and the partnership of Bristol-Myers Squibb (NYSE: BMY) and AstraZeneca (NYSE: AZN). But the path to market proved tricky.

    Johnson and Johnson's Invokana earlier this year became the first SGLT2 approved in the United States. Bristol-Myers and AstraZeneca’s more »

  • The U.S. Antidepressant Market: Old Fashioned Branding Might Save the Day

    By Amod Saul - July 18, 2013 | Tickers: AZN, AZN, LLY, FRX, GSK, PFE, TRGT

    Over 40% of Americans have used an antidepressant at least once during their lifetime and, at 270 million prescriptions per year, antidepressants are the most consumed class of therapeutics in the US. However, revenue does not match prescription numbers due to fierce generic competition in the class. While retail prices for commonly prescribed branded anti-depressants like Cymbalta can reach over $170 per month, a generic equivalent will cost less than more »

  • Can Fish Oil Help This Drug Giant Regain its Mojo?

    By Robert Hanley - July 15, 2013 | Tickers: ACT, AZN, OMTH

    AstraZeneca’s (NYSE: AZN) financial results have been on a downward spiral lately, as patent expirations have led to sharp declines in sales of its leading drugs.  In 2012, the company lost $4.5 billion of sales due to exclusivity expirations in various regions, a portion of which was attributable to its top-selling Crestor cholesterol drug.  In response, management went outside the company to try to protect its cardiovascular franchise more »

  • Expect Huge Upside to This Biotech Stock as It Approaches FDA Approval

    By Kanak Kanti - July 15, 2013 | Tickers: ACAD, AZN, NVS

    About 600,000 people across the US and 4 million people worldwide suffer from PDP, or Parkinson's Disease Psychosis, a debilitating nonmotor complication of Parkinson's disease. At present, there are no effective therapies available for PDP; worse, most drugs for Parkinson's disease can themselves cause PDP, according to NIH. Now, however, there is hope of effective treatment for multitudes of PDP patients from a new molecule being more »

  • This Company Is Surely Not a Depressing Investment

    By Abir Karmakar - July 15, 2013 | Tickers: AZN, JNJ

    According to a study, in any given year, 7% of adults suffer from major depression, and at least one in 10 youths will deal with the disorder at some point during their teenage years. But, about 20% of these cases will not respond to current treatments; for those that do, relief may take weeks to months to come.

    Current solutions, including drugs like Celexa and Prozac, often consume a month more »

  • A Small-Cap Pharmaceutical Company With 2014 in Its Sights

    By Ashley Sales - July 5, 2013 | Tickers: AZN, BMY, MDCO

    A few months back, Barron's featured an intriguing pharmaceutical company that goes by the name The Medicines Company (NASDAQ: MDCO). This stock is said to have strong catalysts that could lift the share price over the years. The company was at $20.40/share in November 2012 and is now trading at $31.60. The company has reported a 52-week high of $37.40.

    The biggest catalyst for a more »

  • AstraZeneca: One Dividend You Won't Want To Miss

    By Rupert Nicholson - July 3, 2013 | Tickers: AZN

    AstraZeneca (NYSE: AZN) is a biopharmaceutical company and it primarily operates in six areas of the healthcare market: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. Its key competitors include Pfizer, Merck & Co., and Johnson & Johnson. Its trailing revenue is $27.009 billion, while it has a net income of $5.683 billion.

    The Dividend

    The firm's dividend has a yield of 5.84%, with a projected yield more »

  • This Anti-Sense Bet Makes Sense

    By Mohsin Saeed - July 1, 2013 | Tickers: AEGR, AZN, ISIS

    In the last couple of years, the biotechnology industry has been on a roll. The large number of drug approvals and the dreaded patent cliff has positively impacted the biotechnology index. This has increased demand for small biotechnology companies with promising candidates and improved across the entire industry.

    Recently, Isis Pharmaceuticals (NASDAQ: ISIS) antisense platform has received a lot of attention. The company uses its antisense technology to eradicate proteins more »

  • Page 1 of 7